Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31290475 | 0.84 | CA12 (0.49) | LMNAALDH1A1 | |
| SCHEMBL20457566 | 0.79 | ALOX5 (0.53) | ALOX5MAOBACACBLMNAL3MBTL1 | |
| SCHEMBL1747136 | 0.76 | FFAR1 (0.72) | MAOBNPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL31579489 | 0.76 | LTA4H (0.60) | ALOX5MAOBACACBLMNAL3MBTL1 | |
| SCHEMBL1745247 | 0.76 | FFAR1 (0.72) | MAOBNPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL1508259 | 0.76 | MAOB (0.57) | ALOX5MAOBACACBNPC1RAB9A | |
| SCHEMBL8770978 | 0.76 | MAOB (0.57) | ALOX5MAOBACACBNPC1RAB9A | |
| SCHEMBL28757877 | 0.75 | ALOX5 (0.58) | ALOX5ACACBLMNAL3MBTL1NPC1 | |
| SCHEMBL6266373 | 0.75 | LTA4H (0.59) | ALOX5MAOBACACBLMNAL3MBTL1 | |
| SCHEMBL2985256 | 0.74 | MAOB (0.56) | ALOX5MAOBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | ALOX5 2328/4885MAOB 3111/4885ACACB 83/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | ALOX5 2328/4885MAOB 3111/4885ACACB 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.